CRB Investigator, Co-Founder of City Therapeutics, Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine
Harnessing next-generation siRNA engineering to improve and expand the therapeutic reach of RNAi-based medicines
Building sustainable product engine for innovative RNAi therapeutics to make a significant impact for patients across multiple disease indications, with first program expected to enter clinical development at or around year-end 2025
Led by founding Alnylam CEO and RNAi therapeutics pioneer John Maraganore, Ph.D., as executive chair and co-founded by key scientists and business leaders in RNAi
Financing led by ARCH Venture Partners with participation from Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures and AN Ventures
CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc. announced its launch today with a vision to lead the future of RNA interference (RNAi)-based medicine. City Therapeutics™ aims to harness next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to build a robust and sustainable product engine and expand the therapeutic reach of RNAi-based medicines. Led by executive chair John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, Inc., the company has completed a $135 million Series A financing led by ARCH Venture Partners, with participation from other leading life sciences investors including Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and other undisclosed investors....read full story here
